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OBJECTIVE: To examine the association between cardiac performance during recovery and the severity of heart
failure, as determined by clinical and cardiopulmonary exercise test responses.
METHODS: As part of a retrospective cohort study, 46 heart failure patients and 13 normal subjects underwent
cardiopulmonary exercise testing while cardiac output was measured using a noninvasive device. Cardiac output in
recovery was expressed as the slope of a single exponential relationship between cardiac output and time; the
recovery-time constant was assessed in relation to indices of cardiac function, along with clinical, functional, and
cardiopulmonary exercise responses.
RESULTS: The recovery time constant was delayed in patients with heart failure compared with normal subjects
(296.7¡238 vs. 110.1¡27 seconds, p ,0.01), and the slope of the decline of cardiac output in recovery was steeper
in normal subjects compared with heart failure patients (p,0.001). The slope of the decline in cardiac output
recovery was inversely related to peak VO2 (r = -0.72, p,0.001) and directly related to the VE/VCO2 slope (r = 0.57,
p,0.001). Heart failure patients with abnormal recovery time constants had lower peak VO2, lower VO2 at the
ventilatory threshold, lower peak cardiac output, and a heightened VE/VCO2 slope during exercise.
CONCLUSIONS: Impaired cardiac output recovery kinetics can identify heart failure patients with more severe
disease, lower exercise capacity, and inefficient ventilation. Estimating cardiac output in recovery from exercise may
provide added insight into the cardiovascular status of patients with heart failure.
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INTRODUCTION
The symptom-limited cardiopulmonary exercise test has
long been an important tool for studying patients with
cardiovascular disease. Its applications include classifying
disease severity, evaluating the effects of therapy, estimat-
ing prognosis, and developing safe and effective exercise
prescriptions.1,2 In recent years, the physiological response
to recovery from exercise has been used to provide insight
into the pathophysiology of cardiovascular disease. For
example, impaired heart rate recovery (HRR) has been used
widely over the last decade to describe a delay in vagal
reactivation and predict outcomes in patients who are
referred for exercise testing for clinical reasons.3-7 The
kinetics of ventilatory gas exchange and cardiac perfor-
mance during recovery have been of particular interest for
patients with chronic heart failure (CHF). Delayed kinetics
of the return of oxygen uptake to baseline levels during
recovery from exercise has been related to CHF severity 8-12
and have been shown to be an independent prognostic
marker.9 Magnetic resonance and near-infrared spectro-
scopy studies have shown that the delay in oxygen uptake
recovery is attributable to a delay in the recovery of muscle
energy stores, skeletal muscle metabolic abnormalities,
microcirculatory changes, and prolonged elevations in
cardiac output, and these responses appear to be indepen-
dent of the exercise level achieved.12,13
The measurement of cardiac performance during recov-
ery from exercise could provide added insight into cir-
culatory impairment and risk stratification in CHF patients.
As with more widely used indices for functionally classify-
ing and estimating risk in CHF patients, impaired cardiac
function is presumably at the foundation of abnormal
recovery responses to exercise, but this issue has not been
fully explored. Two studies have observed delayed cardiac
output recovery in CHF patients using direct Fick measure-
ments, and these studies demonstrated that the degree to
which cardiac output is delayed is related to CHF
severity.14,15 However, direct measurement of cardiac out-
put is impractical for routine clinical use because it is
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invasive and expensive, is associated with additional risk,
and is difficult to measure during and after exercise.
Noninvasive methods, including CO2 rebreathing, bioimpe-
dence, and echocardiography, have been used to measure
cardiac output during exercise, but limitations regarding the
validity and practicality of these techniques have been
widely reported.16-20
If the recovery period is to have a useful clinical
application in CHF, as suggested by recent studies, 7-13
noninvasive techniques that provide reasonably accurate
and easily obtained measures of cardiac function must be
available. One novel, noninvasive approach to quantifying
cardiac function during exercise involves the analysis of
blood flow-dependent changes in the phase shift of
electrical currents applied across the chest.21,22 In contrast
to the bioimpedance approach, which relies on the detection
of flow-dependent changes in electrical signal amplitude,
phase shift detection may be more precise and less subject to
noise. The purpose of the current study was to use this
noninvasive approach to examine the association between
cardiac performance during recovery and CHF severity, as
determined by clinical and cardiopulmonary exercise test
responses.
METHODS
Subjects: This was a retrospective cohort study of clinical
data obtained from 59 consecutive subjects who were
referred to a private cardiology clinic for cardiopulmonary
exercise testing to evaluate dyspnea. The study was
approved by the Texas Tech University of Health Sciences
Committee on the Protection of Human Subjects, and all
patients consented to the use of their data in the
analysis. Forty-six subjects had heart failure (28 with EF
,40%, 18 with normal EF determined by echocardiogra-
phy), and 13 were ultimately diagnosed as normal (normal
EF and peak VO2, with dyspnea based on noncardiac
factors). The normal subjects were not matched with CHF
patients by demographic factors but were used as a
convenience group for comparison. The demographic and
clinical characteristics of the subjects are summarized in
Table 1. All subjects were limited by fatigue or dyspnea
during exercise, and none showed clinical evidence of
pulmonary disease or ischemic changes on ECG.
Exercise Testing. Symptom-limited maximal exercise tests
were performed on a treadmill using a ramp protocol.23
The rate of change in speed and grade was individualized
so that the test was targeted to last the recommended
8-12 minutes.2 The peak speed was 3.0 mph for all subjects.
All subjects were asked to abstain from eating or smoking at
least 3 hours prior to the test. Ventilatory oxygen uptake was
measured using a Medical Graphics Corporation metabolic
system (CPX-D, St. Paul, MN). Oxygen uptake and other
gas exchange data were acquired breath-by-breath, reported
as 30-second averages, and expressed as liters/min. Oxygen
uptake, carbon dioxide production, minute ventilation, and
respiratory exchange ratios were calculated online. A 12-lead
electrocardiogram was monitored continuously and recorded
every minute. Blood pressure was recorded manually every
twominutes throughout the test. All subjects were encouraged
to exert maximal effort; among patients with CHF, the
Borg 0-to-10 perceived exertion scale was used to quantify
effort.24
The ventilatory threshold was determined by two
experienced, independent reviewers using the V-slope
method25 and was confirmed by ventilatory criteria. VE
and VCO2 responses, acquired from the initiation of exercise
to peak exercise, were used to calculate the VE/VCO2 slope
via least-squares linear regression (y = mx + b,
m= slope).26,27 The oxygen uptake efficiency slope (OUES)
was derived by the slope of a semi-log plot of minute
ventilation versus VO2. As such, the OUES estimates the
efficiency of ventilation with respect to VO2, with greater
slopes indicating greater ventilatory efficiency.26,27
Cardiac Output. Cardiac output was estimated at rest,
continuously throughout exercise, and for at least 6 minutes
during the recovery period. Four dual electrodes were used
to obtain cardiac output and other hemodynamic data. The
Table 1 - Demographic and Clinical Characteristics.
Patient characteristics CHF Normal P-value
N 46 13
Age (years) 63¡12 51¡11 0.001
Height (cm) 172.6¡10 171.8¡10 0.81
Weight (kg) 88.7¡23 76.1¡14 0.06
Heart rate 74.8¡13 74.3¡12 0.90
Systolic blood pressure 118¡10 125¡9 0.02
Ejection fraction (%) 42.5¡17 56.5¡9 0.007
Peak VO2 (ml/kg/min) 15.9¡5.6 24.8¡6.2 ,0.001
Peak VO2 (ml/min) 1374¡555 1857¡464 0.007
CHF etiology, # subjects (%) - -
Ischemic cardiomyopathy 19 (41) - -
Idiopathic dilated cardiomyopathy 1 (2) - -
CHF with normal EF* 18 (39) - -
NYHA classification, # (%)
Class I 11 (24) - -
Class II 5 (11) - -
Class III 24 (52) - -
Class IV 6 (13) - -
Medications, # subjects (%)
Digoxin 3 (6) - -
Beta blocker 35 (76) 6 (46) 0.11
ACE/ARB 26 (57) 5 (38) ,0.001
CHF= chronic heart failure; NYHA=New York Heart Association; ACE/ARB=ACE inhibitor/angiotensin receptor blocker; * .45%.
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NICOMH bioreactance-based system (Cheetah Medical Inc.,
Indianapolis, IN) is based on an analysis of the relative
phase shifts that occur when oscillating currents tra-
verse the thoracic cavity. These phase shifts contrast with
traditional bioimpedance-based systems, which rely on
measured changes in signal amplitude. The NICOM
system consists of a radiofrequency generator for creating
a high-frequency current that is injected across the thorax; 4
dual-surface electrodes, used to establish electrical contact
with the body; a receiving amplifier for recording
transthoracic voltage in response to injected current; and
circuitry for determining the relative phase shift between
the injected current and the recorded voltage. Within each
dual electrode, one electrode was used by the high-
frequency current generator, and the other was used by
the input voltage amplifier. Signals were applied to and
recorded from the left and right sides of
the thorax; these signals were processed separately and
averaged after digital processing.
The signal-processing unit of the system determined the
relative phase shift (DW) between the input and output
signals. DW, in turn, reflected changes in blood flow in the
aorta. Stroke volume (SV) was estimated with the formula
SV~C:VET:dW=dtmax,
where C is a constant of proportionality, and VET is
ventricular ejection time, which was determined from the
NICOM and ECG signals. The value of C has been
optimized in prior studies and accounts for patient age,
gender, and body size.28 Age, gender, weight and height are
mandatory inputs that are required before the device begins
monitoring. The constant (C) is modified according to these
specific data for each patient. The constant is derived from a
thorough statistical analysis based on a multivariate regres-
sion between NICOM-derived parameters and cardiac
output as measured by thermodilution. These analyses
have shown that the constant is not affected significantly by
factors other than those listed above, so it remains constant
as calculated for each patient.
Cardiac output (CO) was calculated using the formula
CO~SV:HR,
where HR is heart rate.
NICOM measurements were obtained every minute
during exercise and for 6 minutes into recovery. The time
constant of cardiac output decay in recovery was deter-
mined for the monoexponential relationship between
cardiac output and time during the first 5 minutes of
recovery using the following formula:
Y~y0zAe {x=tð Þ,
where y is cardiac output, y0 is cardiac output at time zero
(beginning of the recovery phase), A and e are constants, x is
the time elapsed, and t is the time constant of decay. This
time constant reflects the time required to achieve 63.2% of
the difference between starting and baseline values. The
recovery slope represents the slope of the linear relationship
between CO and VO2 during recovery, and R
2 represents
the square of the linear fit of these two variables in recovery.
Heart rate and stroke volume in recovery were defined as
the difference between peak values and those measured at
2 minutes postexercise.
Statistical Analysis. For descriptive statistics, compari-
sons between normal subjects and CHF patients were
performed using unpaired t-tests. Response differences
between normal subjects and CHF patients with normal
and abnormal cardiac output in recovery (defined as above
or below the median time constant in recovery of 205
seconds) were assessed using one-way ANOVA. Post-hoc
tests were performed using the Bonferroni method. The
associations between noninvasive cardiac output data,
clinical variables, and other exercise test responses were
assessed using linear regression.
RESULTS
The square of the linear fit (R2) and the slope of the
decline in cardiac output during recovery were lower in
CHF patients compared with normal subjects (R2 = 0.97¡1.6
vs. 0.88¡0.15, p = 0.04, and recovery slope = -13.7¡3.0 vs.
-6.8¡3.2, p,0.001). The recovery time constant was nearly
threefold higher in CHF patients compared with normal
subjects (110.1¡27 vs. 296.7¡328 seconds, p = 0.01).
Exercise test responses among normal subjects, CHF
patients with a normal cardiac output recovery response,
and CHF patients with an impaired cardiac output recovery
response are summarized in Table 2. Overall, the mean
maximal perceived exertion was 7.8¡1.7, and the mean
peak respiratory exchange ratio was 1.12¡0.09, suggesting
that maximal effort was exerted by most patients. Normal
subjects generally achieved higher exercise test responses
than CHF patients, and CHF patients with abnormal
recovery responses had reduced exercise responses com-
pared to those with normal recovery cardiac output. The
mean peak VO2 values for normal subjects and CHF
patients normal and abnormal recovery responses were
24.8¡4, 16.7¡4, and 13.2¡3 ml/kg/min, respectively
(p,0.001). Similarly, oxygen uptake at the ventilatory
threshold was highest among normal subjects and lowest
among CHF patients with impaired cardiac output
responses in recovery. The VE/VCO2 slope was similar
between normal subjects and CHF patients with a normal
cardiac output time constant in recovery (0.28¡0.03 and
0.31¡0.05 respectively, NS), but the VE/VCO2 slope was
heightened among CHF patients with delayed cardiac
output responses during recovery (0.40¡0.09, p,0.05 vs.
the other 2 groups). Similarly, the OUES was not different
between normal subjects (2.1¡0.59) and CHF patients with
normal cardiac output in recovery (1.8¡0.52) but was
reduced in CHF patients with abnormal cardiac output in
recovery (1.2¡0.55, p,0.05 vs. the other 2 groups).
Table 3 shows the differences in resting and peak exercise
cardiac function variables among normal subjects and CHF
patients with normal and delayed cardiac output in
recovery. The resting ejection fraction was higher in normal
subjects than in either CHF group (p,0.01), but resting
cardiac output, cardiac index, peak aortic flow (dX/dt) and
VET were similar among groups. At peak exercise, cardiac
output, cardiac index, and dX/dt did not differ between
normal subjects and CHF patients with a normal recovery
response, but all 3 responses were reduced among CHF
patients with a delayed cardiac output recovery response.
The HRR at 2 minutes postexercise was higher in normal
subjects than in either patient group and was higher in CHF
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patients with normal cardiac output responses in recovery
than in CHF patients with impaired cardiac output in
recovery (47¡18, 31¡18, and 17¡6 beats in normal subjects
and CHF patients with normal and abnormal cardiac output
responses in recovery, respectively, p,0.001). The decline in
stroke volume at 2 minutes in recovery was similar between
normal subjects and CHF patients with normal recovery
cardiac output (72.7¡43 and 71.8¡53 ml, respectively) but
tended to be lower in CHF patients with abnormal cardiac
output in recovery (51.8¡34 ml). This difference repre-
sented cardiac output decreases of 48%, 43%, and 35%
among normal subjects and CHF patients with normal and
Table 2 - Exercise test responses in normal subjects and CHF patients with normal and abnormal cardiac output in
recovery (mean ¡ SD).
Normal CHF and normal CO recovery CHF and abnormal CO recovery p-value
Rest
Standing heart rate (beats/
min)
75¡13 75¡14 76¡14 0.96
Systolic blood pressure
(mmHg)
125¡9 122¡9 117¡8 0.02
Ventilatory threshold
Heart rate (beats/min) 130¡22 104¡32{ 93¡18{ ,0.001
Systolic blood pressure
(mmHg)
140¡7 133¡14 126¡12{ 0.03
Diastolic blood pressure
(mmHg)
84¡7 84¡7 76¡11 0.06
Oxygen uptake (ml/min) 1487¡483 1230¡433 843¡354{* ,0.001
Oxygen uptake (ml/kg/min) 19.8¡6 12.5¡4{ 9.3¡3{ ,0.001
Minute ventilation (l/min) 38.2¡15 33.4¡12 27.6¡11 0.06
CO2 production (ml/min) 1445¡580 1139¡462 776¡353
{* ,0.001
Exercise time (min) 5.3¡3.1 7.6¡4.1 5.4¡3.9 0.13
Perceived exertion -- 4.1¡3.4 4.7¡2.1 0.69
Maximal exercise
Heart rate (beats/min) 139¡24 113¡26{ 108¡21{ 0.001
Systolic blood pressure
(mmHg)
143¡12 136¡13 132¡16 0.10
Oxygen uptake (L/min) 1.857¡0.464 1.579¡0.515 1.113¡0.504{* ,0.001
Oxygen uptake (ml/kg/min) 24.8¡6.2 16.7¡4.9{ 13.2¡4.3{ ,0.001
Minute ventilation (L/min) 63.7¡16 56.1¡18 48.5¡22 0.09
VE/VCO2 slope 0.28¡0.03 0.31¡0.05 0.40¡0.09
{* ,0.001
OUES 2.1¡0.59 1.8¡0.52 1.2¡0.55{* ,0.001
VCO2 (L/min) 2.173¡0.577 1.756¡0.647
{ 1.239¡0.605{* ,0.001
Respiratory exchange ratio 1.15¡0.09 1.09¡0.09 1.13¡0.08 0.18
Exercise time (min) 9.1¡2.1 9.1¡3.4 12.1¡4.8 0.06
Perceived exertion -- 7.5¡2.1 8.2¡1.5 0.50
p-value represents ANOVA main effect between groups.
*p,0.05 vs. CHF and normal recovery.
{p,0.05 vs. normal subjects.
CO= cardiac output.
OUES=oxygen uptake efficiency slope.
VCO2= carbon dioxide production.
Table 3 - Noninvasive cardiac output data at rest and during exercise.
Rest Normal CHF and normal CO recovery
CHF and abnormal CO
recovery p-value
Cardiac output (L/min) 5.45¡1.7 4.90¡1.3 5.16¡1.6 0.55
Cardiac index (L/min/M2) 2.89¡0.78 2.36¡0.60 2.64¡0.86 0.14
Dx/dt (ohme/sec) 171.3¡107 100.1¡63 171.2¡137 0.06
VET (msec) 174.3¡36 163.1¡23 160.4¡15 0.27
Ejection fraction (%) 56.5¡9 40.5¡14{ 41.0¡19{ 0.01
Peak exercise
Cardiac output (L/min) 20.0¡10.0 19.2¡6.6 13.5¡5.4{* 0.02
Cardiac index ((L/min/M2) 10.6¡4.7 9.3¡3.2 6.7¡2.3{ 0.006
Dx/dt (ohme/sec) 557.8¡239 415.7¡214 341.4¡114{ 0.009
VET (msec) 143.6¡17 142.3¡12 152.3¡20 0.13
p-value represents ANOVA main effect between groups.
*p,0.05 vs. CHF and normal recovery.
{p,0.05 vs. normal subjects.
Dx/dt =peak aortic flow.
VET= ventricular ejection time.
cardiac function in recovery in CHF patients
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abnormal cardiac output responses in recovery, respec-
tively.
Similar results were observed when ventilatory and
cardiac function responses during exercise and recovery
were compared between patients with normal and reduced
ejection fraction ($40 or ,40%).
Table 4 presents correlation coefficients between cardiac
performance measurements during exercise and recovery
and key clinical and exercise test responses for the total
study sample combined. Resting indices of cardiac function
were poorly related to the cardiac output recovery slope and
time constant, but significant associations were observed
between cardiac output in recovery and peak VO2, maximal
cardiac output and index, and maximal dX/dt. The
associations between peak VO2, peak cardiac output, and
cardiac output recovery slope for normal and CHF subjects
are illustrated in Figure 1, and the associations between the
VE/VCO2 slope, OUES, and cardiac output recovery slope
for all subjects are illustrated in Figure 2. The cardiac output
recovery slope was inversely associated with peak VO2 (r = -
0.72) and maximal cardiac output (r = -0.50, p,0.01). The
cardiac output recovery slope was significantly related to
the VE/VCO2 slope (r = 0.57, p,0.01) and inversely related
to the OUES (r = -0.58, p,0.01).
DISCUSSION
A great deal of interest has been generated in recent years
regarding recovery from exercise in CHF patients.7-15 These
studies have focused on delays in heart-rate recovery,7
delayed oxygen kinetics,8-13 and accumulated oxygen ‘‘debt’’
in recovery.29 It has been consistently demonstrated that
impaired responses in recovery from exercise are associated
with more severe heart failure and a worse prognosis.7-15 A
number of factors that may contribute to abnormalities in
recovery from exercise in CHF patients have been suggested,
including a vagal reactivation delay, skeletal muscle meta-
bolic abnormalities, microcirculatory changes, and sustained
hyperpnea.7-15 Impairments in ability of cardiac output to
return to normal during recovery from exercise have also
been reported among CHF patients using direct Fick
measurements. Tanabe et al.14 observed an ‘‘overshoot’’ of
cardiac output in recovery from exercise in a subgroup of
CHF patients with impaired cardiac output responses to
exercise and more severe CHF. Other investigators have
reported that abnormal oxygen kinetics in recovery (i.e.,
delayed time constant or half-time of VO2) among CHF
patients parallel a delay in recovery of cardiac output. Reddy
and colleagues,30 using a submaximal isometric protocol,
reported that while cardiac output returned to baseline 90
Figure 1 - The relationships between peak VO2, peak cardiac index, and cardiac output slope in recovery.
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seconds after exercise in normal subjects, cardiac output
remained elevated for a prolonged period after exercise in
patients with the most severe CHF. Similarly, Sumimoto et
al.,15 using a supine cycle ergometer protocol, reported that
the decline in cardiac output 5 minutes postexercise was
significantly elevated in patients with the most severe CHF.
These studies suggest that the measurement of cardiac
output in recovery may provide additional insight into the
circulatory, metabolic, and autonomic abnormalities that
characterize CHF and could have potential applications for
the functional and prognostic assessment of these patients.
However, the use of invasive measurements to quantify
cardiac function in recovery is impractical for routine clinical
purposes. We therefore employed a novel, noninvasive
approach involving the analysis of blood flow-dependent
changes in the phase shift of electrical currents applied across
the chest. This approach differs from the bioimpedance
approach, which relies on detecting flow-dependent changes
in electrical signal amplitude that are inherentlymore difficult
to detect andmore subject to noise disturbances. Accordingly,
this approach (called bioreactance) has an improved signal-to-
noise ratio and is less susceptible to physical factors such as
body habitus, body motion and ambient conditions. In both
preclinical and clinical settings, this method was demon-
strated to provide cardiac output values that were highly
correlated with thermodilution methods 21, and it has been
demonstrated to be valid in CHF patients undergoing
maximal exercise testing.22 To our knowledge, noninvasive
techniques have not previously been used to study CHF
patients’ recovery from exercise. Our objectives were to
determine the feasibility of using this technique in recovery
and to characterize the association between cardiac output in
recovery and CHF severity as assessed by clinical and
cardiopulmonary exercise test variables.
CURRENT FINDINGS
The observation that the degree of cardiac output impair-
ment during recovery was related to CHF severity provides
support for both the application of a noninvasive device and
the clinical relevance of the recovery period among CHF
patients. Our salient findingwas that impaired cardiac output
kinetics in recovery identify CHF patients with more severe
disease, lower exercise capacity, reduced cardiac function at
peak exercise, and inefficient ventilation. This finding was
evidenced by a 30% lower maximal cardiac output in patients
Figure 2 - The relationships between the VE/VCO2 slope, oxygen uptake efficiency slope (OUES), and cardiac output slope in recovery.
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who demonstrated delayed cardiac output recovery kinetics;
conversely, CHF patients with a normal recovery response
had ameanmaximal cardiac output that was similar to that of
normal subjects (Table 3). The cardiac output delay in
recovery appeared to be attributable to delays in both heart
rate and stroke volume. In addition, patients with an
abnormal recovery response demonstrated heightened and
inefficient ventilation, as evidenced by a mean VE/VCO2
slope of 0.40¡0.05, an OUES of 1.2¡0.52 (values above and
below conventional high-risk thresholds, respectively),27 and
the significant relationship between VE/VCO2 slope, OUES
and the recovery time constant (Figure 2). The latter indices
have been widely used in recent years as markers of
ventilatory inefficiency and are strongly related to outcomes
in CHF.26,27 A heightened VE/VCO2 slope and reduced
OUES reflect the degree of ventilation/perfusionmismatch in
the lungs, early lactate accumulation, and abnormal ventila-
tory control, which are hallmarks of more severe CHF.26,27
Limitations. We were only able to quantify the general
pattern of cardiac output in recovery; instantaneous
responses upon exercise cessation, recovery overshoot, 15
the duration of the impaired response in recovery and other
patterns require further study. Because there are few
previous studies in this area, the classification of abnormal
cardiac function in recovery was empirical; there may be
other methods with which to express this response. We did
not have direct measures of cardiac function during recovery
with which to compare the results from the noninvasive
device. The effects of beta blockers and other drugs, age, and
CHF etiology are all likely to influence the recovery response;
however, because our study was retrospective, we were not
able to gain insight into the effects of these factors. Finally, we
used a convenience sample of subjects without CHF as a
comparison group; the normal cardiac output response in
recovery from exercise has not been previously established.
Summary. Impaired cardiac output kinetics in recovery
from exercise identify CHF patients with more severe
disease, lower exercise capacity, and inefficient ventilation,
providing added insight into these patients’ cardiovascular
status. The noninvasive measurement of cardiac
performance in recovery from exercise has potentially
important applications for the functional and prognostic
assessment of patients with CHF.
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